Our efforts are endless to unlock a world of life-changing
transformative medicines by utilizing Artificial Intelligence
BioXcel LLC utilizes advanced technologies such as AI (Artificial Intelligence) to develop transformative medicines at unprecedented speed in multiple therapeutic areas with high unmet needs. We are driven by scientific curiosity and passion for technology and embrace innovative approaches that help patients. We are optimizing research and development for productivity and creating novel and transformative medicines (or drugs).
Our AI-enabled platform, EvolverAI helps reduce development costs and accelerates the drug development timelines for a technologically-enabled, fast and efficient drug discovery process.
With the combination of our in-house human expertise and technological advancement, we can change the paradigm of drug discovery.
BioXcel's AI platform, EvolverAI 2.0, is redefining the future of healthcare by accelerating the discovery and development of innovative medicines. By integrating advanced AI with deep scientific expertise, the platform enables faster, more efficient drug development-exemplified by the launch of IGALMI™ (dexmedetomidine) sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults, achieved in just four years. EvolverAI 2.0 unlocks new therapeutic possibilities, helping us address critical unmet needs while significantly reducing the time, cost, and risk of traditional drug development.
Learn More
Accelerating pharmaceutical innovation by combining human expertise with AI and machine learning—powered by our proprietary EvolverAI® 2.0 platform.
At every step of our journey, we make the most of our in-house scientific expertise. We believe with advanced technologies and well-researched endeavours, together we can create novel discoveries. BioXcel is deeply involved in creating breakthroughs in the following categories of diseases:
Excellence starts at the top. Meet our leaders who inspire us at every step of our journey
CEO & Chairman
COO, BioXcel LLC., USA
Managing Director, BioXcel India
VP, Corporate Strategy & Innovation, BioXcel India
CEO & Chairman
COO, BioXcel LLC., USA
Managing Director, BioXcel, India
Chairman, Scientific Advisory Board
BioXcel Therapeutics, Inc. is a biopharmaceutical company developing transformative medicines in neuroscience and immuno-oncology utilizing AI, and its approaches.
InveniAI® LLC is a global leader in applying AI and ML tools to transform innovation across drug discovery and development by identifying and accelerating transformative therapies for diseases with unmet medical needs.
A leading centre of research and innovation focused on developing transformative treatments. It integrates a rich and diverse cross-functional mix of highly qualified scientific, medical, commercial, IP, and Artificial Intelligence.
With the right combination of human expertise, technology, and science, we can bring positive outcomes in patients’ lives by:
Vast majority of patients dosed completed the full 12-week study Data from more than 2,200 agitation episodes collected...
READ MORE First and only FDA-approved orally dissolving sublingual film for mild, moderate or severe agitation in patients with schizophrenia...
READ MORE - Collaboration enables Kyowa Kirin's R&D team to access InveniAI's data-driven discovery platform in expanded therapeutic areas...
READ MORE
Collaboration to create transformative therapeutics for immune diseases by combining InveniAI's validated AI-based platform, AlphaMeld®,...
READ MORE Much Needed Non-Opioid, Non-Addictive Pain Treatments are the Focus for Pain Therapeutics Development Efforts...
READ MORE BioXcel said today it has joined with Takeda Pharmaceutical’s U.S.-based global development group to repurpose...
READ MORE Email at
careers@bioxcel.com
+1 475 237 9007
Email at
info@bioxcel.com
+1 475 237 9007
